Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (565)	4/1/1999 7:23:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Mike: I spent a year of my life sitting in a cold room, watching a unit gravity sedimentation device separate Sertoli cells from type B spermatogonia. I never want to hear of them again. However.... weird suckers, I'll give you that. Here's the basis for the studies, from what I can find...... Nature 1995 Oct 19;377(6550):630-2 Published erratum appears in Nature 1998 Jul 9;394(6689):133 A role for CD95 ligand in preventing graft rejection. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC Department of Immunology, University of Colorado School of Medicine, Denver 80262, USA. Testis is a remarkable immune-privileged site, long known for its ability to support allogeneic and xenogeneic tissue transplants. Here we have investigated the molecular basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Apo-1) ligand survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligand, were rejected. Further analysis of testis showed that CD95 ligand messenger RNA is constitutively expressed by testicular Sertoli cells, and that Sertoli cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. These findings indicate that CD95 ligand could be used to create immune-privileged tissue for a variety of transplant uses. ************* Way too early Mike. Fun reading, however! Lame news for the past two weeks, really lame news. Grudgingly, I will acknowledge the votes for REGN. Any other nominations from the last two days? BTIM not allowed. It's fine news, but it's not really "biotech" IMO. BCHE (Troxacitabine)?